The stock closed down 1.4% at $26.33 on Friday, while Citigroup's Geoff Meacham kept a Neutral rating and raised his target to $27 from $26.
Ahead of quarterly earnings, attention also turned to Pfizer's 6.53% annual dividend yield, equal to 43 cents a share quarterly or $1.72 annually.
At that rate, investors would need about 3,488 shares worth roughly $91,839 to generate $500 a month in dividend income, though yields can change with share price and payout moves.
Pfizer's dividend exceeds its cash flow. Is this a sign of confidence or a prelude to a painful cut?
Can Pfizer's multi-billion dollar bet on oncology and obesity drugs rescue it from its looming patent cliff crisis?